Burning Rock Biotech (NASDAQ:BNR) Issues Quarterly Earnings Results

Burning Rock Biotech (NASDAQ:BNR) issued its quarterly earnings results on Tuesday. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($2.29) by $2.04, FiscalAI reports. The company had revenue of $15.66 million for the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative return on equity of 9.98% and a negative net margin of 10.27%.

Burning Rock Biotech Trading Down 1.5%

Shares of NASDAQ:BNR opened at $9.07 on Tuesday. Burning Rock Biotech has a 1-year low of $2.95 and a 1-year high of $41.72. The firm has a market capitalization of $95.42 million, a PE ratio of -11.48 and a beta of 1.33. The business’s 50 day moving average is $16.06 and its 200-day moving average is $21.35.

Insider Buying and Selling at Burning Rock Biotech

In other news, Director Yusheng Han acquired 314,870 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The shares were bought at an average price of $17.36 per share, with a total value of $5,466,143.20. Following the acquisition, the director owned 17,672,676 shares of the company’s stock, valued at $306,797,655.36. This trade represents a 1.81% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 30.30% of the company’s stock.

Institutional Trading of Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. Marshall Wace LLP acquired a new position in shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned approximately 0.10% of Burning Rock Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 30.03% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.